Although both ETAR antagonist (ambrisentan) and dual ETAR/ETBR antagonist (bosentan) have been approved for treatment of PAH [38], selective antagonists for ETAR and ETBR appeared to have different effects on PAH. Here, EDNRA is linked to pulmonary arterial hypertension.